KIRYAT SHMONA, Israel — As you drive toward the industrial park in this border town, you pass a disquieting sight: the abandoned skeleton of a thread factory that shuttered 18 years ago. Broken glass litters the concrete floor, and behind a door condemned with “NO PASSAGE” in red spray paint, huge canisters lean against one another like dead bodies.

It’s a foreboding omen of what could happen if the world’s largest generic drug manufacturer, Teva Pharmaceutical Industries, were to pull out of this northern Israeli city.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy